New combo before surgery aims to control advanced lung cancer
NCT ID NCT07264647
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of chemotherapy and immunotherapy (tislelizumab) given before surgery for people with stage III PD-L1 positive non-small cell lung cancer. The goal is to see if this approach helps more patients have successful surgery to remove all cancer. About 30 adults who are current or past smokers and have no specific genetic mutations will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Istituti Fisioterapici Ospitalieri
RECRUITINGRome, Roma (RM), 00144, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••